
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4658574/publications.pdf Version: 2024-02-01



IOHAN M KROS

#	Article	IF	CITATIONS
1	Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell, 2017, 31, 737-754.e6.	7.7	836
2	Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro-Oncology, 2017, 19, 162-174.	0.6	381
3	cIMPACTâ€NOW update 6: new entity and diagnostic principle recommendations of the cIMPACTâ€Utrecht meeting on future CNS tumor classification and grading. Brain Pathology, 2020, 30, 844-856.	2.1	363
4	cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathologica, 2020, 139, 603-608.	3.9	344
5	Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet, The, 2017, 390, 1645-1653.	6.3	307
6	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncology, The, 2016, 17, 484-495.	5.1	274
7	Human USP18 deficiency underlies type 1 interferonopathy leading to severe pseudo-TORCH syndrome. Journal of Experimental Medicine, 2016, 213, 1163-1174.	4.2	224
8	The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. Neuro-Oncology, 2018, 20, 103-112.	0.6	220
9	Panel Review of Anaplastic Oligodendroglioma From European Organization for Research and Treatment of Cancer Trial 26951. Journal of Neuropathology and Experimental Neurology, 2007, 66, 545-551.	0.9	143
10	Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. Neuro-Oncology, 2016, 18, 388-400.	0.6	143
11	Diffuse Infiltrating Oligodendroglioma and Astrocytoma. Journal of Clinical Oncology, 2017, 35, 2394-2401.	0.8	142
12	Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts. Drug Discovery Today, 2018, 23, 1175-1182.	3.2	142
13	Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. Neuro-Oncology, 2020, 22, 515-523.	0.6	140
14	Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas. Neuro-Oncology, 2015, 17, 935-941.	0.6	136
15	Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC) Tj ETQq1 Oncology, The, 2021, 22, 813-823.	1 0.7843 5.1	14 rgBT /O 132
16	Recurrent noncoding U1ÂsnRNA mutations drive cryptic splicing in SHH medulloblastoma. Nature, 2019, 574, 707-711.	13.7	129
17	The contribution of tumor-associated macrophages in glioma neo-angiogenesis and implications for anti-angiogenic strategies. Neuro-Oncology, 2017, 19, 1435-1446.	0.6	121
18	A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics. Neuro-Oncology, 2017, 19, 614-624.	0.6	100

#	Article	IF	CITATIONS
19	Identification of Tumor-Related Proteins by Proteomic Analysis of Cerebrospinal Fluid from Patients with Primary Brain Tumors. Journal of Neuropathology and Experimental Neurology, 2003, 62, 855-862.	0.9	98
20	Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification. Acta Neuropathologica, 2017, 134, 957-959.	3.9	87
21	Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathologica, 2018, 136, 227-237.	3.9	86
22	Glut1/SLC2A1 is crucial for the development of the bloodâ€brain barrier in vivo. Annals of Neurology, 2010, 68, 835-844.	2.8	84
23	Molecular Evolution of <i>IDH</i> Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study. Journal of Clinical Oncology, 2020, 38, 81-99.	0.8	84
24	Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas. Cancer, 2006, 106, 388-395.	2.0	83
25	Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. Lancet Oncology, The, 2018, 19, 1170-1179.	5.1	80
26	Circulating glioma biomarkers. Neuro-Oncology, 2015, 17, 343-60.	0.6	73
27	Breast cancer brain metastasis: molecular mechanisms and directions for treatment. Neuro-Oncology, 2018, 20, 1439-1449.	0.6	66
28	Diagnostic Detection of Allelic Losses and Imbalances by Next-Generation Sequencing. Journal of Molecular Diagnostics, 2016, 18, 775-786.	1.2	64
29	T lymphocytes facilitate brain metastasis of breast cancer by inducing Guanylate-Binding Protein 1 expression. Acta Neuropathologica, 2018, 135, 581-599.	3.9	63
30	Expression site of P2RY12 in residential microglial cells in astrocytomas correlates with M1 and M2 marker expression and tumor grade. Acta Neuropathologica Communications, 2017, 5, 4.	2.4	61
31	CMTM4 regulates angiogenesis by promoting cell surface recycling of VE-cadherin to endothelial adherens junctions. Angiogenesis, 2019, 22, 75-93.	3.7	61
32	Increased levels of circulating endothelial progenitor cells and circulating endothelial nitric oxide synthase in patients with gliomas. Annals of Neurology, 2007, 62, 40-48.	2.8	59
33	Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues. Acta Neuropathologica, 2014, 128, 879-891.	3.9	54
34	In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2009-2018.	1.8	54
35	Grading of Gliomas: The Road From Eminence to Evidence. Journal of Neuropathology and Experimental Neurology, 2011, 70, 101-109.	0.9	51
36	Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical researchâ€practice gaps, challenges, and insights. Medicinal Research Reviews, 2018, 38, 325-376.	5.0	50

#	Article	IF	CITATIONS
37	The transcriptional landscape of Shh medulloblastoma. Nature Communications, 2021, 12, 1749.	5.8	47
38	Activation of CECR1 in M2-like TAMs promotes paracrine stimulation-mediated glial tumor progression. Neuro-Oncology, 2017, 19, now251.	0.6	44
39	Low-grade glioma harbors few CD8 T cells, which is accompanied by decreased expression of chemo-attractants, not immunogenic antigens. Scientific Reports, 2019, 9, 14643.	1.6	44
40	A Proteome Comparison Between Physiological Angiogenesis and Angiogenesis in Glioblastoma. Molecular and Cellular Proteomics, 2012, 11, M111.008466.	2.5	41
41	Improving the characterization of endothelial progenitor cell subsets by an optimized FACS protocol. PLoS ONE, 2017, 12, e0184895.	1.1	41
42	Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion–Positive Supratentorial Ependymomas. Cancer Discovery, 2021, 11, 2230-2247.	7.7	39
43	Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics. Acta Neuropathologica Communications, 2018, 6, 126.	2.4	38
44	Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. Neuro-Oncology, 2021, 23, 1547-1559.	0.6	34
45	Subgroup and subtype-specific outcomes in adult medulloblastoma. Acta Neuropathologica, 2021, 142, 859-871.	3.9	34
46	A unified 3D map of microscopic architecture and MRI of the human brain. Science Advances, 2022, 8, eabj7892.	4.7	33
47	Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. Acta Neuropathologica, 2021, 141, 945-957.	3.9	32
48	Differential expression of Hela-type caldesmon in tumour neovascularization: a new marker of angiogenic endothelial cells. Journal of Pathology, 2005, 205, 408-414.	2.1	30
49	Contemporary frameless intracranial biopsy techniques: Might variation in safety and efficacy be expected?. Acta Neurochirurgica, 2015, 157, 2011-2016.	0.9	30
50	CMTM3 (CKLF-Like Marvel Transmembrane Domain 3) Mediates Angiogenesis by Regulating Cell Surface Availability of VE-Cadherin in Endothelial Adherens Junctions. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1098-1114.	1.1	30
51	Myocarditis in patients with subarachnoid hemorrhage: A histopathologic study. Journal of Critical Care, 2016, 32, 196-200.	1.0	28
52	Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i> -wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial. Clinical Cancer Research, 2022, 28, 2527-2535.	3.2	27
53	TMX2 Is a Crucial Regulator of Cellular Redox State, and Its Dysfunction Causes Severe Brain Developmental Abnormalities. American Journal of Human Genetics, 2019, 105, 1126-1147.	2.6	25
54	Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma. Journal of Neuro-Oncology, 2018, 139, 349-357.	1.4	24

#	Article	IF	CITATIONS
55	Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. Journal of Clinical Oncology, 2022, 40, 2539-2545.	0.8	23
56	The Association Between the Extent of Glioblastoma Resection and Survival in Light of MGMT Promoter Methylation in 326 Patients With Newly Diagnosed IDH-Wildtype Glioblastoma. Frontiers in Oncology, 2020, 10, 1087.	1.3	22
57	Mutation specific functions of EGFR result in a mutation-specific downstream pathway activation. European Journal of Cancer, 2015, 51, 893-903.	1.3	21
58	Evidence-Based Diagnostic Algorithm for Glioma: Analysis of the Results of Pathology Panel Review and Molecular Parameters of EORTC 26951 and 26882 Trials. Journal of Clinical Oncology, 2015, 33, 1943-1950.	0.8	21
59	Periostin Is Expressed by Pericytes and Is Crucial for Angiogenesis in Glioma. Journal of Neuropathology and Experimental Neurology, 2020, 79, 863-872.	0.9	20
60	Dopamine D2 receptor expression in the corticotroph cells of the human normal pituitary gland. Endocrine, 2017, 57, 314-325.	1.1	19
61	Long-term follow-up results of EORTC 26951: A randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD) Journal of Clinical Oncology, 2012, 30, 2-2.	0.8	19
62	Analysis of immunoglobulin H gene rearrangement by polymerase chain reaction in primary central nervous system lymphoma. Journal of Neurosurgery, 2002, 97, 1390-1396.	0.9	18
63	Comparative proteomic analysis of cat eye syndrome critical region protein 1- function in tumor-associated macrophages and immune response regulation of glial tumors. Oncotarget, 2018, 9, 33500-33514.	0.8	18
64	Pregnancy Zone Protein is Increased in the Alzheimer's Disease Brain and Associates with Senile Plaques. Journal of Alzheimer's Disease, 2015, 46, 227-238.	1.2	17
65	Cell proliferation and migration are mutually exclusive cellular phenomena in vivo: Implications for cancer therapeutic strategies. Cell Cycle, 2009, 8, 950-951.	1.3	15
66	Potential Molecular Signatures Predictive of Lung Cancer Brain Metastasis. Frontiers in Oncology, 2018, 8, 159.	1.3	15
67	Fast Tracking of Co‣ocalization of Multiple Markers by Using the Nanozoomer Slide Scanner and NDPViewer. Journal of Cellular Physiology, 2014, 229, 967-973.	2.0	14
68	Expression Sites of Colligin 2 in Glioma Blood Vessels. Brain Pathology, 2010, 20, 50-65.	2.1	13
69	Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation. Frontiers in Oncology, 2020, 10, 596.	1.3	13
70	Mapping tumour heterogeneity with pulsed 3D CEST MRI in non-enhancing glioma at 3ÂT. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2022, 35, 53-62.	1.1	13
71	Peptide profiling of cerebrospinal fluid by mass spectrometry. Expert Review of Proteomics, 2006, 3, 297-309.	1.3	12
72	Medulloblastoma has a global impact on health related quality of life: Findings from an international cohort. Cancer Medicine, 2020, 9, 447-459.	1.3	11

#	Article	IF	CITATIONS
73	Mutations targeting the coagulation pathway are enriched in brain metastases. Scientific Reports, 2017, 7, 6573.	1.6	10
74	Intratumoral Distribution of 1p Loss in Oligodendroglial Tumors. Journal of Neuropathology and Experimental Neurology, 2007, 66, 1118-1123.	0.9	9
75	Flow cytometry shows added value in diagnosing lymphoma in brain biopsies. Cytometry Part B - Clinical Cytometry, 2018, 94, 928-934.	0.7	9
76	Differences in spatial distribution between WHO 2016 low-grade glioma molecular subgroups. Neuro-Oncology Advances, 2019, 1, vdz001.	0.4	9
77	Elusive Neurotoxicity in T Cell-Boosting Anticancer Therapies. Trends in Immunology, 2019, 40, 274-278.	2.9	7
78	DNA-nanorobot-guided thrombin-inducing tumor infarction: raising new potential clinical concerns. Drug Discovery Today, 2020, 25, 951-955.	3.2	7
79	Intratumoral, not circulating, endothelial progenitor cells share genetic aberrations with glial tumor cells. Journal of Cellular Physiology, 2013, 228, 1383-1390.	2.0	6
80	A Method to Correlate mRNA Expression Datasets Obtained from Fresh Frozen and Formalin-Fixed, Paraffin-Embedded Tissue Samples: A Matter of Thresholds. PLoS ONE, 2015, 10, e0144097.	1.1	6
81	Phosphorylation Ratio Determination in Fresh-Frozen and Formalin-Fixed Paraffin-Embedded Tissue with Targeted Mass Spectrometry. Journal of Proteome Research, 2020, 19, 4179-4190.	1.8	6
82	Case report: a fatal combination of hemophagocytic lymphohistiocytosis with extensive pulmonary microvascular damage in COVID-19 pneumonia. Journal of Hematopathology, 2021, 14, 79-83.	0.2	6
83	Long-term follow-up results of EORTC 26951: A randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD) Journal of Clinical Oncology, 2012, 30, 2-2.	0.8	6
84	Circulating Proangiogenic Cells and Proteins in Patients with Glioma and Acute Myocardial Infarction: Differences in Neovascularization between Neoplasia and Tissue Regeneration. Journal of Oncology, 2019, 2019, 1-13.	0.6	5
85	Immune-Related Circulating miR-125b-5p and miR-99a-5p Reveal a High Recurrence Risk Group of Pancreatic Cancer Patients after Tumor Resection. Applied Sciences (Switzerland), 2019, 9, 4784.	1.3	4
86	Differential Expression of BOC, SPOCK2, and GJD3 Is Associated with Brain Metastasis of ER-Negative Breast Cancers. Cancers, 2021, 13, 2982.	1.7	4
87	Haemoglobin staining for in vivo portraying of functional vasculature in experimental zebrafish embryos. Biochemical and Biophysical Research Communications, 2009, 380, 823-824.	1.0	3
88	Circulating angiogenic cells in glioblastoma: toward defining crucial functional differences in CAC-induced neoplastic versus reactive neovascularization. Neuro-Oncology Advances, 2020, 2, vdaa040.	0.4	3
89	Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial. Clinical Cancer Research, 2022, 28, 2440-2448.	3.2	3
90	Novel Antibody–Peptide Binding Assay Indicates Presence of Immunoglobulins against EGFR Phospho-Site S1166 in High-Grade Glioma. International Journal of Molecular Sciences, 2022, 23, 5061.	1.8	2

#	Article	IF	CITATIONS
91	Circulation status of subintestinal vessels is a sensitive parameter for monitoring suboptimal systemic circulation in experimental zebrafish embryos. Cell Cycle, 2009, 8, 3782-3783.	1.3	1
92	Challenge of the gap between the current mania of cancer stem cells and the therapeutic strategy for patients with cancer. International Journal of Cancer, 2010, 126, 1529-1530.	2.3	1
93	Glioblastoma Multiforme. Journal of Neuropathology and Experimental Neurology, 2005, 64, 260.2-260.	0.9	0
94	AT-34CONSTRUCTION OF AN INTEGRATED DIAGNOSTIC ALGORITHM CONSISTING OF CONSENSUS HISTOLOGIC AND MOLECULAR PARAMETERS OF TWO EORTC TRIALS ON ANAPLASTIC GLIOMA. Neuro-Oncology, 2014, 16, v16-v16.	0.6	0
95	IMMU-02. PROTEOMIC ANALYSIS IDENTIFIED CECR1 MEDIATED RESPONSE IN MACROPHAGE AND TUMOR ASSOCIATED MACROPHAGE. Neuro-Oncology, 2018, 20, i98-i99.	0.6	0
96	NIMC-75. WHO 2016 GRADE II GLIOMA MOLECULAR SUBTYPES HAVE A DISTINCT SPATIAL DISTRIBUTION PATTERN. Neuro-Oncology, 2018, 20, vi192-vi192.	0.6	0
97	HGG-04. PERICYTE-DERIVED PERIOSTIN IS CRUCIAL FOR NEO-VESSEL FORMATION IN GLIOMA. Neuro-Oncology, 2018, 20, i89-i89.	0.6	0
98	BSCI-25. THE ROLE OF THE IFNÎ ³ PATHWAY IN BREAST CANCER BRAIN METASTASIS FORMATION. Neuro-Oncology Advances, 2019, 1, i5-i5.	0.4	0
99	EPEN-10. UNRAVELLING THE TUMOR IMMUNE MICROENVIRONMENT OF POSTERIOR FOSSA A EPENDYMOMAS ON RNA AND PROTEIN EXPRESSION LEVELS. Neuro-Oncology, 2021, 23, i15-i15.	0.6	0
100	Panel review of a set of anaplastic oligodendroglioma of EORTC trial 26951: interobserver variation, correlation with 1p/19q loss and clinical outcome. FASEB Journal, 2007, 21, A26.	0.2	0
101	Cerebral Metastasis of Common Cancers. Cancers, 2021, 13, 65.	1.7	0